Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Immunohistochemical Assessment of Programmed Death Ligand 1 PDL-1 and Autophagy Marker LC3B in Glioblastoma

NCT04284306 is registered in ClinicalTrials.gov with Assiut University as lead sponsor.

NCT NCT04284306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04284306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Immunohistochemical Assessment of Programmed Death Ligand 1 PDL-1 and Autophagy Marker LC3B in Glioblastoma
Lead sponsor
Assiut University
Phase
Observational
Overall status
Unknown status
Start date
March 1, 2020
Completion date
September 30, 2022
Enrollment
61 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme